In state 6, the high expression of the PI3K/AKT/mTOR pathway coupled with low expression of Toll-like receptors may lead to abnormal tumour proliferation and immune escape, thereby limiting the effectiveness of immunotherapy (Figure 3A,C,H) [16]. The gene discussed is AKT1; the disease is neoplasm.